Literature DB >> 22877502

Epidemiology and risk factors of urothelial bladder cancer.

Maximilian Burger1, James W F Catto, Guido Dalbagni, H Barton Grossman, Harry Herr, Pierre Karakiewicz, Wassim Kassouf, Lambertus A Kiemeney, Carlo La Vecchia, Shahrokh Shariat, Yair Lotan.   

Abstract

CONTEXT: Urothelial bladder cancer (UBC) is a disease of significant morbidity and mortality. It is important to understand the risk factors of this disease.
OBJECTIVE: To describe the incidence, prevalence, and mortality of UBC and to review and interpret the current evidence on and impact of the related risk factors. EVIDENCE ACQUISITION: A literature search in English was performed using PubMed. Relevant papers on the epidemiology of UBC were selected. EVIDENCE SYNTHESIS: UBC is the 7th most common cancer worldwide in men and the 17th most common cancer worldwide in women. Approximately 75% of newly diagnosed UBCs are noninvasive. Each year, approximately 110 500 men and 70 000 women are diagnosed with new cases and 38 200 patients in the European Union and 17 000 US patients die from UBC. Smoking is the most common risk factor and accounts for approximately half of all UBCs. Occupational exposure to aromatic amines and polycyclic aromatic hydrocarbons are other important risk factors. The impact of diet and environmental pollution is less evident. Increasing evidence suggests a significant influence of genetic predisposition on incidence.
CONCLUSIONS: UBC is a frequently occurring malignancy with a significant impact on public health and will remain so because of the high prevalence of smoking. The importance of primary prevention must be stressed, and smoking cessation programs need to be encouraged and supported.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22877502     DOI: 10.1016/j.eururo.2012.07.033

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  584 in total

1.  Association of FokI polymorphism of vitamin D receptor with urothelial bladder cancer in Tunisians: role of tobacco smoking and plasma vitamin D concentration.

Authors:  Mohamed Kacem Ben Fradj; Amani Kallel; Mohamed Mourad Gargouri; Mohamed Ali Ben Chehida; Ahmed Sallemi; Yassine Ouanes; Sami Ben Rhouma; Jemaa Riadh; Moncef Feki; Yassine Nouira; Naziha Kaabachi
Journal:  Tumour Biol       Date:  2015-11-28

2.  The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.

Authors:  Konrad Steinestel; Stefan Eder; Konstantin Ehinger; Juliane Schneider; Felicitas Genze; Eva Winkler; Eva Wardelmann; Andres J Schrader; Julie Steinestel
Journal:  Tumour Biol       Date:  2015-11-30

3.  Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.

Authors:  Liansheng Ren; Xihua Yang; Lili Zhao; Hong Zhang; Jing Wang
Journal:  Integr Cancer Ther       Date:  2015-08-27       Impact factor: 3.279

4.  Partitioning of time trends in prevalence and mortality of bladder cancer in the United States.

Authors:  Igor Akushevich; Arseniy P Yashkin; Brant A Inman; Frank Sloan
Journal:  Ann Epidemiol       Date:  2020-06-03       Impact factor: 3.797

5.  Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Authors:  Richard M Turner; Chun S Kwok; Chen Chen-Turner; Chinedu A Maduakor; Sonal Singh; Yoon K Loke
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

6.  Oncological safety and quality of life in men undergoing simultaneous transurethral resection of bladder tumor and prostate: results from a randomized controlled trial.

Authors:  Marco Dellabella; Alessandro Branchi; Luca Gasparri; Redi Claudini; Daniele Castellani
Journal:  World J Urol       Date:  2018-05-03       Impact factor: 4.226

7.  Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Authors:  J Palou; F Pisano; R Sylvester; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; A J Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E K Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; P Gontero
Journal:  World J Urol       Date:  2018-05-02       Impact factor: 4.226

8.  Clinical significance of random bladder biopsy in primary T1 bladder cancer.

Authors:  Masafumi Otsuka; Satoru Taguchi; Tohru Nakagawa; Teppei Morikawa; Shigekatsu Maekawa; Jimpei Miyakawa; Akihiko Matsumoto; Hideyo Miyazaki; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yasuhiko Igawa; Yukio Homma
Journal:  Mol Clin Oncol       Date:  2018-03-08

9.  Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.

Authors:  Aihua Xu; Md Ahsanul Kabir Khan; Fangzhi Chen; Zhaohui Zhong; Han-Chun Chen; Yuanda Song
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

10.  Dietary Inflammatory Index and Risk of Bladder Cancer in a Large Italian Case-control Study.

Authors:  Nitin Shivappa; James R Hébert; Valentina Rosato; Marta Rossi; Massimo Libra; Maurizio Montella; Diego Serraino; Carlo La Vecchia
Journal:  Urology       Date:  2016-09-29       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.